Brea C. Lipe, MD describes the unique treatment technology explored in the PERSEUS phase three trial.
This segment focuses on a large, 700+ patient randomized phase three trial conducted by the European Myeloma Network comparing a quadruplet drug regimen (lenalidomide, bortezomib, dexamethasone, and subcutaneous daratumumab) to a triplet regimen without daratumumab for multiple myeloma. The quadruplet regimen demonstrated improved progression-free and overall survival compared to the triplet. The use of subcutaneous daratumumab makes the regimen more convenient for patients than prior intravenous regimens. While efficacy and safety are most important, convenience is a consideration for many patients in terms of quality of life and logistics. This trial provides evidence that this quadruplet regimen is effective and more convenient for patients.
Summary was AI-generated and edited for clarity.